A Phase I, Open Interaction Study Between Oral Doses of GLPG0634 (200 mg QD) and Single Oral Doses of Midazolam (2 mg) in Healthy Subjects

Trial Profile

A Phase I, Open Interaction Study Between Oral Doses of GLPG0634 (200 mg QD) and Single Oral Doses of Midazolam (2 mg) in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2014

At a glance

  • Drugs Filgotinib (Primary) ; Midazolam
  • Indications Anxiety disorders; Epilepsy; Insomnia; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Feb 2013 New source identified and integrated (NCT01798979: ClinicalTrials.gov).
    • 24 Feb 2013 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top